To print: Select File and then Print from your browser's menu

Title: Brimonidine-Purite Comparable to Brimonidine Alone in Lowering Intraocular Pressure

URL: http://ipsapp002.lwwonline.com/content/getfile/3523/8/7/abstract.htm

J Glaucoma 2002 April;11(2):119-126. "Twelve-Month Evaluation of Brimonidine-Purite Versus Brimonidine in Patients With Glaucoma or Ocular Hypertension"
04/26/2002 08:05:00 AM
By Mark Moran

Brimonidine-purite 0.15% and 0.2%, appears to decrease intraocular pressure comparably to brimonidine 0.2% in patients with glaucoma or ocular hypertension. Jay Katz, MD, of the Brimonidine-Purite Study Group, Wills Eye Hospital, Philadelphia, Pennsylvania, United States headed this 12-month, randomized, multi-center study of the two drugs--with brimonidine-Purite tested at two different concentrations. The group found that brimonidine-Purite 0.15% showed the most favorable safety and tolerability profile and a reduced incidence of allergic conjunctivitis. It also showed a better satisfaction and comfort rating. There were no statistically significant differences in mean intraocular pressure or mean changes from baseline intraocular pressure (at peak or trough) among groups receiving either drug. Difference in mean intraocular pressure between patients receiving brimonidine-purite-0.15% and those receiving brimonidine-0.2% treatment group was less than 1 mmHg. The relative percent difference in allergic conjunctivitis was 41% lower in the brimonidine-purite 0.15% group compared with the brimonidine 0.2% group. The comfort and satisfaction rating significantly favored brimonidine-Purite 0.15%, he reports. In the study, 381 patients were randomly assigned to receive brimonidine-Purite 0.15%, 383 received brimonidine-Purite 0.2%, and 383 received brimonidine 0.2%. All patients received the drugs three times daily, and mean intraocular pressure at baseline was similar in the three treatment groups. Diurnal intraocular pressure was measured four times daily at baseline, week six, and at three months, six months, and 12 months. Intraocular pressure was also measured twice daily at week two and month nine. Safety was evaluated by adverse events and other ocular and systemic measures.

http://ipsapp002.lwwonline.com/content/getfile/3523/8/7/abstract.htm

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.